Couple of reasons
"Led to a circa 65% reduction in tumour size in mice treated with the combination
therapy" Combo therapy, not enough detail in announcement to say if INV043 showed any real benefit over the approved PD-1 being used.
"Tumours were also significantly smaller than those in mice that received monotherapy"
Ok, great. Where's the detail? What dose were the treatment arm given?
Devil is in the detail, and there's not enough here.
Ann: INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPY, page-15
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.6¢ |
Change
-0.004(4.00%) |
Mkt cap ! $8.199M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.6¢ | $5.005K | 50.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75868 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 278199 | 3 |
View Market Depth
| Last trade - 15.03pm 31/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |